Duloxetine for the treatment of generalized social anxiety disorder: A preliminary randomized trial of increased dose to optimize response

CNS Spectrums

Volumn 15, Issue 7, 2010, Pages 436-443

  Simon, Naomi M ^a   Worthington, John J ^a   Moshier, Samantha J ^a   Marks, Elizabeth H ^a   Hoge, Elizabeth A ^a   Brandes, Mina ^a   Delong, Hannah ^a   Pollack, Mark H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; PLACEBO;

ADULT; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG OVERDOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EFFECT SIZE; FATIGUE; FEMALE; GENERALIZED SOCIAL ANXIETY DISORDER; HOSPITALIZATION; HUMAN; HYPOMANIA; INSOMNIA; LIEBOWITZ SOCIAL ANXIETY DISORDER SCALE SCORE; LIVER FUNCTION TEST; MALE; NAUSEA; NERVOUSNESS; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHABDOMYOLYSIS; SCORING SYSTEM; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PHOBIA; SYNCOPE; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE; XEROSTOMIA;

EID: 79951660538     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900000365     Document Type: Article

References (22)

1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602.
2. Van Ameringen MA, Lane RM, Walker JR, et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry. 2001;158(2):275-281.
3. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA. 1998;280(8):708-713.
4. Stein MB, al. e. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology. 2005;177(3):280-288.
5. Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology. 2005;177(3):280-288.
6. Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD. A randomized, doubleblind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry. 2002;63(1):66-74.
7. Dunner DL, Goldstein DJ, Mallinckrodt C, Lu Y, Detke MJ. Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety. 2003;18(2):53-61.
8. Fava M, Martinez JM, Greist J, et al. The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study. Ann Clin Psychiatry. 2007;19(3):187-195.
9. Koponen H, Allgulander C, Erickson J, et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry. 2007;9(2):100-107.
10. Crippa JA, Filho AS, Freitas MC, Zuardi AW. Duloxetine in the treatment of social anxiety disorder. J Clin Psychopharmacol. 2007;27(3):310.
11. Lin CC. Duloxetine treatment of social anxiety disorder with comorbid major depression. J Clin Psychopharmacol. 2008;28(5):591-592; author reply 592-593.
12. Scott EL, Pollack MH, Otto MW, Simon NM, Worthington JJ. Clinician response to treatment refractory panic disorder: a survey of psychiatrists. J Nerv Ment Dis. 1999;187(12):755-757.
13. First MS, Gibbon M, Williams JBW. Structured Clinical Interview for Axis I DSM-IV Disorders Patient version (SCID-1/P version 2.0). New York, NY: New York State Psychiatric Institute Biometrics Research Department; 1994.
14. Doyle AC, Pollack MH. Establishment of remission criteria for anxiety disorders. J Clin Psychiatry. 2003;64(Suppl 15):40-45.
15. Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry. 1999;60(Suppl 22):29-34.
16. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(Suppl 3):89-95.
17. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321-326.
18. Rapaport MH, Davidson JR. The efficacy of new pharmacological treatments for panic disorder: evaluating the trials. Psychopharmacol Bull. 1998;34(2):167-168.
19. Schneier FR, Heckelman LR, Garfinkel R, et al. Functional impairment in social phobia. J Clin Psychiatry. 1994;55(8):322-331.
20. Davidson JR. Pharmacotherapy of social anxiety disorder: what does the evidence tell us? J Clin Psychiatry. 2006;67(Suppl 12):20-26.
21. Kornstein SG, Dunner DL, Meyers AL, et al. A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy. J Clin Psychiatry. 2008;69(9):1383-1392.
22. Cymbalta delayed-release capsules. In: Physician's Desk Reference. 63rd ed. Montvale, NJ: Thomson PDR; 2009.